Connect Biopharma Holdings Limited Sponsored ADR

CNTB Healthcare Biotechnology

Connect Biopharma Holdings Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $64,000.00, down 99.8% from fiscal 2024. In the quarter to June 2026, revenue grew 296.6%, EPS fell 17.4%, free cash flow fell 23.5% and total debt fell 61.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.91 0.00 0.00%
Market cap
$57.1M
P/E
0.0×
Fwd P/E
−2.0×
Dividend yield
—
F-score
n/a
Altman Z
−5.94
Beneish M
681.78
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(140.51%) (102.94%) (82.72%) (59.42%)

+8 more TTM periods

ROA
(109.34%) (84.59%) (70.51%) (52.44%)
ROIC
0.00% 0.00% 0.00% (3,150.18%)
Return on Tangible Assets
(266.15%) (155.01%) (134.91%) (89.42%)
Average Days of Receivables
868.05 3,522.98 0.00 1,440.10
Free Cash Flow per Share
(0.96) (1.01) (0.93) (0.77)
Free Cash Flow
(60.58) (57.25) (51.64) (43.00)
Capital Expenditures
— — (0.43) (0.73)
Other line items
Cash ROIC
(103.47%) (64.37%) (59.57%) (38.88%)
Accounts Receivable Turnover
0.46 0.15 0.00 0.40
Accounts Payable Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
0.00 0.00 0.00 0.00
Tax Rate
0.00 0.00 0.00 0.01
Research and Development Expense of Revenue
1,789.24% 4,961.87% 0.00% 1,653.31%
Selling, General and Administrative Expense of Revenue
655.51% 2,177.44% 0.00% 1,018.53%
Share Based Compensation of Revenue
143.05% 427.82% 0.00% 212.52%
Operating CF/Net income
0.88 0.89 0.92 0.86
Depreciation/Fixed assets
0.19 0.19 0.18 0.17
Capex/Depreciation
0.00 0.00 (0.61) (1.07)
Revenue per Share
0.05 0.02 0.00 0.04
Operating CF per Share
(0.96) (1.01) (0.92) (0.76)
Capex per Share
0.00 0.00 (0.01) (0.01)
Capex to Sales
0.00 0.00 0.00 0.37

Fold the line items

Columns are period end dates